BIO-MICRO · Biomarkers and Intervention Outcomes in Micronutrient Optimization
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2026-03-01 → 2030-02-28
- Финансиране от ЕС
- 3 933 202 €
- Участници
- 14
- Схема
- HORIZON-TMA-MSCA-DN
Линиите свързват координатора с партньорите.
Накратко на български
Микронутриентите при тежко болни пациенти се изследват чрез търсене на нови маркери за дефицит, като например нивата им в левкоцитите. Този подход помага за разработването на персонализирана терапия вместо прилагането на еднакви дози за всички.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
European micronutrient (MN) guidelines explicitly recommend to replete any MN deficiency in critically ill patients. MNs are crucial for immune defence, cellular metabolism and as antioxidant. Critically ill patients have increased requirements for MNs which can result in severe deficiencies and worse clinical outcomes. There are currently no accurate methods to diagnose MN deficiencies in critically ill patients. MN plasma concentrations are substantially affected by inflammation. MN concentrations in erythrocytes and leukocytes or new functional markers may better reflect real deficiencies. Furthermore, most intervention trials with high-dose MN monotherapy yielded mixed results on clinical outcomes. Due to the absence of accurate monitoring tools of MN body status, all patients received fixed high-dose MN monotherapy. Personalized MN therapy based on subphenotyping of patients and accurate estimation of individual metabolic demands in all phases of disease may yield better outcome than this one-size-fits-all strategy. In addition, more insight in the complex interplay between MNs and the role of MNs in post-ICU phase is necessary to guide future trials. BIO-MICRO consists of physicians, biologists, methodologists, trialists, health scientists, clinical chemists, patient representatives and industrial participants and aims to train innovative research fellows with interdisciplinary and intersectoral skills to develop the urgently needed strategies for MN personalized therapy in critically ill patients. They will develop new analytics for reliably determination MN body status, investigate subphenotypes of patients likely to benefit from MN therapy, enable guidance with appropriate timing of MN therapy, investigate the interplay between MNs and explore the role of MNs in the rehabilitation phase. This will ultimately lead to significantly decreased mortality and organ dysfunctions, shorter ICU stay, improvement of quality of life and significant cost reductions.
Оригинален текст от CORDIS (на английски).
Участници
- STICHTING AMSTERDAM UMC · AmsterdamКоординаторНидерландия
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN · BerlinГермания
- DEUTSCHES INSTITUT FUER ERNAEHRUNGSFORSCHUNG POTSDAM REHBRUECKE · NuthetalГермания
- DeWolfPact b.v. · The HagueНидерландия
- Diagnotix BV · AppingedamНидерландия
- RANDOX TEORANTA · DonegallИрландия
- REINER HAGA MEDISCH DIAGNOSTISCH CENTRUM BV · DelftНидерландия
- STICHTING VU · AmsterdamНидерландия
- STICHTING ZIEKENHUIS GELDERSE VALLEI · Ede GldНидерландия
- Stichting Martini Ziekenhuis · GroningenНидерландия
- UNIVERSITA DEGLI STUDI DI FOGGIA · FoggiaИталия
- UNIVERSITAET POTSDAM · PotsdamГермания
- UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT · WURZBURGГермания
- WAGENINGEN UNIVERSITY · WageningenНидерландия
Връзки
Данни: CORDIS, © Европейски съюз